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A preliminary account of this study was presented at the Twelfth Annual Meeting of the American Association of
Pharmaceutical Scientists, Boston, MA, November 2-6, 1997 (Mehvar R. 1997. Targeted delivery of
methylprednisolone using a dextran prodrug. Pharm Res 14:S336)

Abstract
Plasma and tissue disposition of a macromolecular prodrug of methylprednisolone (MP),
dextran (70 kDa)-methylprednisolone succinate (DMP), was studied in rats. Single 5-mg/kg
doses of DMP or unconjugated MP were administered into the tail veins of different groups of
rats (n = 4/group/time point). Blood (cardiac puncture) and tissues (liver, spleen, kidney, heart,
lung, thymus, and brain) were collected at various times after DMP (0-96 h) or MP (0-2 h)
injections. Concentrations of DMP and MP in samples were analyzed by size-exclusion and
reversed-phase HPLC methods, respectively. Conjugation of MP with 70-kDa dextran resulted in
22-, 300- and 30- fold decreases in the steady state volume of distribution, clearance, and
terminal plasma rate constant of the steroid, respectively. As for tissue distribution, the conjugate
delivered the steroid primarily to the spleen and liver as indicated by 19- and 3-fold increases,
respectively, in the tissue:plasma AUC ratios of the steroid. On the other hand, the tissue:plasma
AUC ratios of the prodrug in other organs were negligible. Active MP was released from DMP
slowly in the spleen and liver, and AUCs of the regenerated MP in these tissues were 55- and
4.8-fold, respectively, higher than those after the administration of the parent drug. In contrast,
no parent drug was detected in the plasma of DMP-injected rats. These results indicate that DMP
may be useful for the targeted delivery of MP to the spleen and liver where the active drug is
slowly released.
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INTRODUCTON
Glucocorticoids, such as methylprednisolone (MP), have been widely used for prevention of
graft rejection in organ transplantation.1-4

However, even at moderate doses, chronic

administration of these steroids results in many side effects such as diabetes, hypertension,
cushing syndrome, and osteoporosis.5 Therefore, selective delivery of glucocorticoids to the
immune system such as the liver and spleen would be advantageous for improving the efficacy
and reducing side effects of these drugs in organ transplantation. Indeed, studies6,7 using
liposomal formulations of MP have shown that enhanced delivery of the steroid to the spleen
would result in an improved survival rate in experimental organ transplantation.
As an alternative to liposomes, polymers such as dextrans may be used as
macromolecular carriers for targeted delivery of immunosuppressive drugs to their site of action
(i.e. reticuloendothelial system). Dextrans are glucose polymers which have long been used as
plasma volume expanders.8 Due to their rich and easily modifiable hydroxyl groups and their
low immunogenicity, dextrans have been extensively investigated as macromolecular carriers to
deliver drugs to target organs9,10 or tumor cells.11-13 Recently, our laboratory showed14,15 that
the tissue accumulation of dextrans was influenced by the molecular weight (Mw) of the
macromolecule. For example, dextran with Mw of 70 kDa (dextran-70) was mainly accumulated
in the liver and spleen.15 In addition, it has been suggested16 that the kinetics of dextran
conjugates are mainly governed by dextran carriers. Therefore, we hypothesized that dextran-70
may be an appropriate candidate for the selective delivery of MP and other immunosuppressive
drugs to the liver and spleen.
Dextran-methylprednisolone succinate (DMP), a conjugate of MP and dextran containing
two ester bonds, was previously synthesized17 using succinic acid as a linker between the
3

polymer and MP (Scheme I).10 Hydrolysis studies10,18 showed that at physiological pH, DMP is
slowly hydrolyzed at both ester bonds (Scheme I), resulting in the formation of MP and
methylprednisolone succinate (MPS), the latter being subsequently converted to MP. Therefore,
the present investigation was designed to determine the plasma and tissue disposition of DMP
and its hydrolysis products after the intravenous administration of the conjugate to rats. For
comparison, the plasma and tissue disposition of MP after the injection of an equivalent dose of
the parent drug was also investigated. The hypothesis of this investigation was that the
conjugation of MP with dextran 70 kDa would result in targeted delivery of MP to the
reticuloendothelial system.

EXPERIMENTAL SECTION
Materials
Dextran-70, 6α-methylprednisolone (MP), and internal standard (triamcinolone acetonide) were
obtained from Sigma Chemical (St. Louis, MO). 6α-methylprednisolone 21-hemisuccinate
(MPS) and methylprednisone (MPN) were purchased from Steraloids (Wilton, NH). For
chromatography, HPLC grade acetonitrile (Mallinckrodt Chromar HPLC) was obtained from
VWR Scientific (Minneapolis, MN). All other reagents were analytical grade. The DMP
conjugate was synthesized from dextran-70 and MPS based on published methods.10,17 The
degree of substitution of MP on DMP (8%, w/w) was determined as described before.17 The
conjugation drastically changed the water solubility of MP from negligible (parent drug) to more
than 20 mg/mL (250 mg/mL of the conjugate).
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Animals
The procedures involving animals used in this study were consistent with the guidelines set by
the National Institute of Health (NIH publication #85-23, revised 1985) and approved by our
Institutional Animal Care and Use Committee. Adult male Sprague Dawley rats (201-250g) were
obtained from Charles River Lab (Wilmington, MA) and housed in a 12-h light-dark cycle and
temperature-controlled facility at least 2 days prior to the experiments. The animals had free
access to drinking water and rat chow before and during the course of experiments. A total of 56
animals were used for this study. Fifty-two rats were divided into two groups. One group (28
rats) was treated with DMP, and another group (24 rats) was treated with MP. The remaining
four rats were used as organ donors for blank samples. The mean ± SD of the body weights of
rats were 223 ± 11 and 218 ± 13 g for DMP- and MP-injected groups, respectively.

Dosing and Sample Collection
Dosing solution of DMP was prepared by dissolving 62.5 mg DMP in 1 mL HPLC water. Based
on a degree of substitution of 8%,17 the strength of this solution was equivalent to 5 mg/mL of
MP. Dosing solution of MP (5 mg/mL) was prepared as reported before.19
Under mild ether anesthesia, single 5-mg/kg (MP equivalent) doses of MP or DMP were
administered into the tail veins of rats. At various times after dosing, animals were sacrificed by
means of carbon dioxide, and liver, spleen, right kidney, heart, lung, thymus, and brain were
collected. Blood samples were also withdrawn by cardiac puncture. The samples were collected
at the following times: 1 min and 2, 5, 12, 24, 48, and 96 hours for DMP-injected rats, and 1, 10,
20, 40, 60, and 120 min for MP-injected rats (n = 4/group/time point).
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Immediately after excision, the collected tissues were rinsed in ice-cold saline solution to
remove excess blood. Afterwards, the tissues were blotted dry and kept frozen until analysis.
After centrifugation of the blood in a pre-chilled and heparin-coated microcentrifuge tube, the
resultant plasma sample was divided into two portions. One hundred µL of plasma sample was
transferred to a silicon-coated microcentrifuge tube for DMP analysis.20 For unconjugated MP
analysis, 500 µL of plasma sample was transferred to a pre-chilled glass tube containing 100 µL
of a 10% acetic acid solution to prevent DMP hydrolysis in vitro.21 Both plasma and tissue
samples were kept frozen at – 80oC until analysis.
Sample Analysis
The concentrations of DMP in plasma were measured by using a size-exclusion HPLC method.20
Using a 100 µL sample, the assay has a lower limit of quantitation of ≤ 2 µg/mL with intra- and
inter-run CVs of < 6% and error values of < 5%. The concentrations of MPS, MP, and MPN in
plasma were analyzed simultaneously by using a reversed-phase HPLC method.21 Utilizing a 0.5
mL sample, the lower limit of quantitation of the reversed-phase assay is ≤ 0.1 µg/mL for all the
analytes with intra- and inter-run CVs of <16% and error values of < 8% for all the components.
Organs were first homogenized in 3 volumes of 2% glacial acetic acid solution, and the
resultant homogenates were used for drug measurements. Previous studies18 have shown that in
the presence of acetic acid, no hydrolysis of DMP occurs during the storage (up to three weeks at
-80oC) and sample analysis. For measurement of MPS, MP, and MPN in the tissues, the
homogenates were treated similar to plasma21 with one exception: instead of a mobile phase of
0.1 M acetate buffer (pH 5.7): acetonitrile (77:23), which was used for plasma,21 the mobile
phase was 0.1 M phosphate buffer (pH 5.8) :acetonitrile (77:23) for the tissues. The slight change
in the aqueous part of the mobile phase was necessary to separate MPS from a small endogenous
6

peak in some tissue homogenates. The recovery of the analytes from all the tissues was very
similar to that reported21 for the plasma (>80%).
For measurement of DMP in tissue homogenates, a modified version of the previously
reported20 plasma assay was used. Briefly, to 100 µL of tissue homogenates were added 50 µL
of 0.4 M phosphate buffer (pH 7.0), 50 µL of methanol, and 20 µL of perchloric acid (70%).
After a brief vortex-mixing and centrifugation, 170 µL of the supernatant was transferred to a
new microcentrifuge tube, and DMP was precipitated by the addition of 1 mL ethanol. The
supernatant after centrifugation was decanted and the tube dried under a nitrogen stream. The
residue was then dissolved in 200 µL 0.1 M KH2PO4: acetonitrile (65:35), and 100 µL was
injected into HPLC. The conjugate was detected (λ = 250 nm) after analysis of samples on a
size-exclusion column (Polysep-GFC; Phenomenex, Torrance, CA, USA) with a mobile phase of
0.1 M KH2PO4: acetonitrile (75:25, v/v), run at a flow rate of 1 mL/min. The lower limit of
quantitation of this assay was 1 µg/mL based on a 100-µL homogenate sample, and the tissue
recovery from the homogenates was ≥70%.
Pharmacokinetic Analysis
Non-compartmental analysis was performed by using WinNonlin™3.1 computer program
(Pharsight Co.; Mount View, California). Terminal elimination rate constant (λz) was estimated
from the log-linear portion of the plasma or tissue concentration-time courses. Area under the
plasma or tissue concentration-time curve (AUC) was estimated from the average plasma
concentrations at different time points using linear trapezoidal rule with extrapolation to infinity.
Other estimated pharmacokinetic parameters included: mean residence time (MRT), apparent
total body clearance (CL), volume of distribution at steady-state (Vss), terminal volume of
distribution (Vz), maximum observed drug concentration (Cmax), and time to reach Cmax (Tmax).
7

The maximum concentrations of DMP or MP in plasma (C0) after the injection of the conjugate
or parent drug were assumed to be the same as the concentrations at the first sampling time (1
min). The percentage of the total dose in plasma at different times was calculated from the
plasma concentration (Cp) and plasma volume (Vp) by

Cp ⋅Vp ⋅100
. The percentage of the total
Dose

dose in each analyzed tissue was calculated from the tissue concentration of drug (Ct) and
experimental tissue weight (Wt) by

Ct ⋅Wt ⋅100
. For kidneys, percentage of the total dose found
Dose

in the right kidney was multiplied by two to account for both kidneys. The concentrations of
drugs in tissues were corrected15 for the residual blood using the volume fraction (VB) of blood
in different organs; VB values of 0.0135, 0.061, 0.0459, 0.0572, 0.175, 0.321, and 0.0088 were
used for brain, heart, kidney, liver, lung, spleen, and thymus, respectively.22
Statistical Analysis
Because of destructive sampling procedure used for the collection of blood and tissues from
different animals at each time point, the composite kinetic parameter AUC could not be obtained
for individual rats.15 Therefore the variance of AUC was estimated by a reported23,24 procedure
based on the standard error of mean and number of samples at each time point. The pairwise
comparison of AUCs was then carried out at an α level of 0.05 and a Bonferroni-adjusted α of
0.05 or 0.0167 for pairwise comparison of two (1 comparison) or three (3 comparison) means,
respectively. The critical values of Z (Zcrit) for the two-sided test using the Bonferroni-adjusted α
of 0.05 and 0.0167 were 1.96 and 2.39, respectively, and the observed Z (Zobs) was calculated as
reported before.23,24 A Zobs value > Zcrit was used as an indication of a significant difference
between the AUCs.
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The differences among animal groups in their kinetic parameters which could be
estimated for individual rats (e.g., Cmax and C0) were determined using a two-tailed unpaired t
test (for comparison of 2 means) or ANOVA with subsequent Scheffe' F test (for comparison of
3 means) at a significance level (α) of 0.05. When possible, data are presented as mean ± SD.

RESULTS
Plasma Pharmacokinetics
Figure 1 depicts the mean plasma concentration–time courses of DMP and MP after the injection
of equivalent doses of the conjugated or unconjugated drug to rats. After the injection of the
unconjugated MP, the drug was eliminated rapidly and could not be detected at ≥ 2 h (Fig. 1).
However, relatively high concentrations of DMP were detected in plasma until 24 h after the
injection of the conjugate. Whereas the decline in the MP concentrations in plasma was
apparently mono-exponential during the 1-h sampling period, DMP concentrations declined
multi-exponentially (Fig. 1). Interestingly, no unconjugated drug was detected in plasma of
DMP-injected rats.
Table 1 summarizes the estimated plasma pharmacokinetic parameters after MP and
DMP injections. Attachment of MP to dextran-70 resulted in significant changes in the plasma
disposition of the drug. The steady-state volume of distribution, total body clearance, and
terminal elimination rate constant of DMP were 22-, 300- and 30-fold lower than the
corresponding values for the parent drug (Table 1).
After the injection of DMP, no MPS, MP, or the metabolite MPN was detected in the
plasma of animals. Additionally, the concentrations of the metabolite MPN were below the level
of quantitation of the assay (0.1 µg/mL)21 after the administration of the unconjugated MP.
9

Tissue Pharmacokinetics
After the injection of DMP, the intact conjugate or regenerated MP was not found in kidney,
heart, lung, thymus or brain. However, high concentrations of DMP and regenerated MP were
found in the liver and spleen (Figure 2). The high concentrations of DMP in these tissues
persisted up to the last sampling time (96 h). In addition, after the injection of DMP, the
concentrations of the regenerated MP could be measured up to 24 h in the liver and spleen
(Figure 2). The relatively high concentrations of the regenerated MP in the liver and spleen after
DMP injection (Fig. 2) suggest that the conjugate releases MP in these tissues. However, the
concentrations of MPS and MPN were below the limit of quantitation of the assay (0.1 µg/mL)21
in these tissues. In contrast to the profiles of MP regenerated after DMP injection, the hepatic
and splenic concentrations of MP after the injection of the unconjugated MP declined rapidly
and could not be detected beyond 2 h (Fig. 2).
The liver and spleen pharmacokinetic parameters for DMP- and MP-injected rats are
summarized in Table 2. Comparing DMP kinetics (DMP-injected rats) with those of MP (MPinjected rats), the following changes in the tissue pharmacokinetic parameters were observed:
conjugation of MP to dextran-70 resulted in 800- and 6000-fold increases in the AUCs of the
steroid in the liver and spleen, respectively. Additionally, values of MRT for DMP in the liver
and spleen were, respectively, 48- and 230-fold higher than those for MP (Table 2). Conjugation
also resulted in a substantial decrease in λz values in both spleen and liver (Table 2).
Comparing the MP regenerated from DMP (DMP-injected rats) with MP after the
injection of the unconjugated drug (MP-injected rats), the following changes in the tissue
pharmacokinetic parameters were observed: conjugation to dextran increased absolute
availability (i.e., AUC) of the unconjugated MP to the tissue by 4.8-fold in the liver and 55-fold
10

in the spleen (Table 2). In addition, the terminal rate constants of the regenerated MP in both
spleen and liver were substantially smaller than those after the injection of MP (Table 2).
The percentages of the total dose found in plasma and different tissues as DMP or MP are
depicted in Figure 3 after MP or DMP injections. For DMP (DMP-injected rats), percentage of
the total dose in plasma initially decreased rapidly from 74% to 4.9 % within the first 2 h after
the injection. Thereafter, the decline in the percentage of the dose in plasma became slower.
Percentage of the total dose in the liver as DMP first showed an increase from zero to a
maximum of 29% at 2 h and then gradually decreased, reaching a value of 4.2% at the last
sampling time (96 h). The time course of the percentage of the total dose in the spleen as DMP
paralleled that of DMP in the liver with a maximum of 5.5% at 12 h (Fig. 3).
For MP regenerated in DMP-injected rats (Figure 3, top), the percentage of the total dose
in the liver reached a maximum value of 0.55% at 5 h, then decreased to 0.089% at 24 h. In the
spleen, the highest percentage of the total dose as regenerated MP was found at 12 h after DMP
injection (0.17%), and then the percentage decreased to 0.050 % at 24 h (Fig. 3, top).
In contrast to the primary delivery of DMP to the spleen and liver, MP was found in all
the studied organs, except brain, after the injection of the parent drug (Fig. 3, bottom). The first
sampling time immediately after dosing with MP (1 min) contained the highest percentages of
MP in tissues (Fig. 3, bottom). The percentage values were highest in the liver (3.2%), followed
by plasma (1.3%), kidney (0.97%), lung (0.84%), heart (0.67%), spleen (0.48%), and thymus
(0.088%). Thereafter, the percentages in all the studied tissues declined very rapidly and became
undetectable at 2 h after the injection of the free steroid (Fig. 3, bottom).
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DISCUSSION
In rats, MP is a drug with a relatively high volume of distribution.19 In addition, it is reported25
that MP distributes to organs such as liver, spleen, lung, heart, muscle, kidney, and thymus,
achieving higher concentrations in most of these tissues than in plasma. Our results in MPinjected rats (Table 1 and Fig. 3) are in agreement with these reports.19,25 Conjugation of MP
with dextran-70 drastically altered the distribution of the steroid by converting MP from a large
volume of distribution drug (2290 mL/kg) to a prodrug with a small volume of distribution (102
mL/kg) (Table 1). In addition to reducing the volume of distribution of MP, conjugation with
dextran resulted in a primary distribution of the prodrug into the liver and spleen (Table 2 and
Fig. 3) with negligible distribution to any other studied tissues.
As for clearance, MP has a high and dose-dependent clearance in rats.19,26 Conjugation
to dextran-70 converted MP from a high clearance drug (125 mL/min per kg) to a prodrug with a
very low clearance (0.413 mL/min per kg). In a previous study,19 clearance values of 70 and 37
mL/min per kg were reported after 10- and 50-mg/kg doses of MP. Our higher clearance value of
125 mL/min per kg (Table 1) obtained after a lower dose (5 mg/kg) of MP is consistent with the
nonlinearity26 in the clearance of the steroid. Nevertheless, a clearance of 125 mL/min per kg is
>2 fold greater than the rat liver blood flow of ~ 55 mL/min per kg,27 suggesting that MP is also
eliminated by extrahepatic pathways in this species.
The pharmacokinetics and tissue distribution pattern of DMP (Tables 1 and 2) resemble
those14,15 of the carrier polymer dextran-70. The reported15 clearance of 0.5 mL/min per kg for
fluorescein-labeled dextran-70 (FD-70) is very close to that of DMP estimated in our present
study (0.4 mL/min/kg). However, Vss of DMP (102 mL/kg) appears to be larger than that
estimated14 for FD-70 (62 mL/kg). The larger Vss of DMP, compared with FD-70, is not
12

unexpected because dextrans are very water soluble macromolecules28. Therefore, conjugation
with MP, a lipophilic drug with an octanol:water partition coefficient of ~70,19 is expected to
increase the lipophilicity of the carrier and possibly facilitate its distribution to tissues.
Nevertheless, the significant distribution of DMP to the spleen and liver (Fig. 2) and lack of
substantial distribution to other tissues are consistent with the distribution behavior of the carrier
dextran.15
The tissue:plasma AUC ratio of the active drug is a more appropriate measure of the
targetability of a drug to specific tissues than the absolute tissue concentrations or AUCs. Recent
studies29 in our laboratory demonstrated that DMP by itself lacks a significant
immunosuppressive activity and should release MP in order to be effective.

Therefore, a

comparison of the tissue:plasma AUC ratios of the unconjugated MP after the administration of
MP and DMP should determine the usefulness of dextran conjugation for targeted delivery of the
steroid. After DMP injection, no parent drug was detected in plasma, whereas relatively high
concentrations of the parent drug were regenerated from the conjugate in the liver and spleen
(Table 2 and Fig. 2). Consequently, the actual liver or spleen:plasma AUC ratios of the parent
drug after DMP injection could not be calculated. However, lack of detection of parent drug in
plasma, after DMP injection, indicates a high degree of targeted delivery to the spleen and liver,
compared with liver or spleen:plasma AUC ratios of <3 estimated after the injection of the
unconjugated MP (Table 2).
The lack of detection of the parent drug in plasma after the injection of DMP is consistent
with an in vitro study18 demonstrating that DMP is relatively stable in rat blood with a
hydrolysis half life of ~ 25 h. Further, it was suggested18 that the hydrolysis of DMP in blood
occurs via chemical hydrolysis rather than enzymatic hydrolysis by esterases present in blood.
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The lack of enzymatic hydrolysis of ester conjugates of dextrans has been attributed to the large
size of dextrans of high Mw (e.g., dextran 70).16 However, it has been suggested16 that lower Mw
dextran-drug ester conjugates are susceptible to enzymatic hydrolysis. Because dextranase
enzymes, which are responsible for the depolymerization of dextrans, are reportedly30 not
present in blood, only chemical hydrolysis is expected in this media. On the other hand, the
highest concentrations of dextranases have been found in tissues such as the liver and spleen.30
Therefore, dextranases may reduce the Mw of DMP in these tissues, making them more
susceptible to enzymatic hydrolysis by the esterases and subsequent release of the parent drug, as
observed in our studies (Fig. 2).
In a series of studies,6,25,31-33 Jusko and colleagues prepared a liposomal formulation of
MP and investigated the pharmacokinetics and pharmacodynamics of the formulation. The
liposomal formulation selectively delivered the drug to the reticuloendothelial system with a 77fold increase in the spleen:plasma AUC ratio when compared with the parent drug.31
Additionally, it was shown that the liposomal formulation enhanced the tissue receptor
occupancy31 and immunosuppressive effects6,32 of the steroid, hence improving survival rates in
an experimental heart transplantation model.6,34 Despite these promising results, the use of
liposomes may not be ideal for delivery of all immunosuppressive drugs. This is because of
potential problems with the relatively short stability of most liposomal formulations and the
relatively limited drug load which may require higher than acceptable lipid loads injected to the
patients. The targeted delivery of MP using the dextran prodrug approach reported here is an
alternative to the use of liposomes for the delivery of the steroids and other immunosuppressive
drugs to the immune system.
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Dextrans have also been investigated recently35 as macromolecular carriers for the
delivery of the immunosuppressive drug tacrolimus (FK-506). In this study, tacrolimus
conjugated to a negatively charged (carboxymethyl) dextran with a Mw of 70 kDa achieved a
plasma AUC which was 2000-fold higher than that of the free drug. However, the spleen
accumulation of the conjugate was only modestly higher than that after the parent drug
administration. The apparent difference between dextran-tacrolimus35 and dextran-MP (present
study) in their splenic accumulation is most likely due to the differences in the electric charge of
the carriers; whereas Yura et al.35 used a negatively charged dextran for tacrolimus conjugation,
we used a neutral dextran for conjugation with MP. Previous studies36 have shown that the
negatively charged dextrans achieve higher plasma concentrations and lower tissue (e.g., liver
and spleen) accumulations, compared with neutral or positively charged dextrans. Nevertheless,
dextran macromolecules appear to be suitable for improving the pharmacokinetics of a variety of
immunosuppressive drugs.
In

an

attempt

to

reduce

the

toxicity

and

increase

the

effectiveness

of

immunosuppressants, local immunosuppression at the site of transplantation has been
advocated.37 This strategy is based on recent evidence indicating that in addition to the inhibition
of the systemic immune system (such as inhibition of splenic lymphocytes), the inhibition of
intragraft immune events at the site of transplantation is a major determinant of graft
survival.1,37 Therefore, the relatively high concentrations of DMP in the liver, shown in the
present study, may also be advantageous for local immunosuppression in the case of liver
transplantation.
In conclusion, conjugation of methylprednisolone with dextran 70 kDa drastically altered
the pharmacokinetics of the steroid in rats. The conjugate was relatively stable in plasma and
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primarily accumulated in the reticuloendothelial system (e.g., the liver and spleen) where it
gradually released the parent drug. Dextran conjugation may be an effective strategy for targeted
delivery of MP and other immunosuppressive agents to their site of action.
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Table 1— Plasma Pharmacokinetic Parameters (Mean ± SD) of
unconjugated (MP) and Dextran-Conjugated (DMP)
Methylprednisolone after a Single iv Dose (5 mg/kg, MP Equivalent)
of MP or DMP
MP-Injected Rats

DMP-Injected Ratsa

MP

DMP

Co, µg/mL

2.11 ± 0.47†

120 ± 31

Vz, mL/kg

2280b

226b

Vss, mL/kg

2290b

102b

AUC, µg h/mL

0.665 ± 0.048†

202 ± 17

Cl, mL/min per kg

125b

0.413b

MRT, h

0.305b

4.10b

λz, h-1

3.30b

0.110b

T1/2(λz), h

0.210b

6.32b

Parameter

a

No MP was detected in plasma after DMP injection.

b

Standard

deviations could not be determined because of destructive sampling
method.

†

Significantly different (p < 0.05) from the corresponding

value for the DMP-injected rats.
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47.5a
0.0193a
33.5 ± 9.2¶

1.00a
0.954a
3.67 ± 3.25¶
0

MRT, h

λz, h-1

Cmax, µg/mL

Tmax,h

5

0.637 ± 0.152¶

0.0996a

12.1a

-b

9.34 ± 0.89†

MP

Regenerated

0

5.60 ± 1.35§

2.91a

0.325a

2.48a

1.65 ± 0.14‡

MP

MP-Injected Rats

12

106 ± 28§

0.0131a

74.5a

48.0a

9700 ± 731‡

DMP

12

4.38 ± 1.71§

0.126a,c

15.5a

-b

90.6 ± 10.2‡

MP

Regenerated

DMP-Injected Rats

Spleen

§
a

Standard deviations could not be determined because of destructive sampling method.

b
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Could not be

Significant differences for spleen Cmax values between the MP and DMP groups and between DMP and

Significant differences for liver Cmax values between the MP and DMP groups and between DMP and

determined because no parent drug was found in plasma after DMP injection. c Based on two samples only.

Regenerated MP groups.

Regenerated MP groups.

¶

Significantly different from the liver AUC values for the other two means. ‡ Significantly different from the spleen AUC values for

the other two means.

†

7.62a

2.92a

Tissue:Plasma AUC ratio

2

1540 ± 76†

DMP

DMP-Injected Rats

1.94 ± 0.23†

MP

MP-Injected Rats

Liver

AUC, µg h/g

Parameter

Methylprednisolone after a Single iv Dose (5 mg/kg, MP Equivalent) of MP or DMP

Table 2—Liver and Spleen Pharmacokinetic Parameters (Mean ± SD) of Unconjugated (MP) and Dextran-Conjugated (DMP)

Legends for Figures

Scheme 1. Chemical structure of dextran-methylprednisolone succinate

Figure 1. Plasma concentration–time courses of conjugated (DMP) and unconjugated (MP)
methylprednisolone after iv administration of single 5-mg/kg doses (MP equivalent) of MP or
DMP. Standard deviation values are shown as error bars (n = 4 for each point).

Figure 2. Liver (top) and spleen (bottom) concentration–time courses of parent (MP) and/or
conjugated (DMP) methylprednisolone after iv administration of single 5-mg/kg doses (MP
equivalent) of MP or DMP. Standard deviation values are shown as error bars (n = 4 for each
point). The insets depict the tissue concentration-time courses of the unconjugated MP after the
injection of the parent drug (open circles) or the dextran-conjugated steroid (closed circles).

Figure 3. The percentage of the total dose of the conjugated (DMP) and/or unconjugated (MP)
methylprednisolone found in plasma and sampled tissues at various times after the iv
administration of DMP (top) or parent drug (bottom). For comparison purposes, the time axis is
the same for both the top and bottom figures. The inset for the bottom figure depicts the
percentage values during the first hour after the administration of MP.
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